+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Serum leptin levels and body weight in postmenopausal women under transdermal hormone replacement therapy



Serum leptin levels and body weight in postmenopausal women under transdermal hormone replacement therapy



European Journal of Medical Research 5(2): 63-66



Leptin, the adipocyte-specific product of the ob gene, is implicated in body weight regulation and energy balance. We investigated the influence of hormone replacement therapy (HRT) on the body mass index (BMI) and serum leptin levels in 20 postmenopausal, nonobese women treated with transdermal HRT (delivery rate 50 microg 17beta-estradiol/24 h, 1 patch per week) for 6 months. Serum leptin levels were measured by ELISA and results were compared by means of the Student's paired t-test or Pearson's correlation. The mean patient age was 55+/-6.04 years. The mean body weight prior to the start of the study was 69.39+/-9.37 kg, and the BMI before HRT was 26.92+/-4.47 kg/m2. Both parameters remained unchanged under therapy. No significant change in absolute serum leptin values (18.8+/-8.4 ng/ml; 20.47+/-9.7 ng/ml; 17.92+/-8.7 ng/ml at 0, 4 and 6 months respectively) or in adiposity-corrected values (serum leptin/BMI) (0.68+/-0.24; 0.75+/-0.29; 0.67+/-0.26 at 0, 4 and 6 months respectively) were found. Serum leptin levels correlated well with BMI (r = 0.7193, p<0.0001). There was no significant correlation of estradiol with serum leptin levels before or during therapy. In summary, low dose, transdermal HRT exhibited no influence on serum leptin levels or BMI in postmenopausal women. These data suggest that low dose HRT does not influence body weight regulation in postmenopausal women.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 047346812

Download citation: RISBibTeXText

PMID: 10720565


Related references

Serum leptin levels in postmenopausal women: effects of transdermal hormone replacement therapy. Menopause 7(1): 36-41, 2000

Changes in leptin, tumor necrosis factor and lipoprotein levels in postmenopausal women with transdermal hormone replacement therapy. International Journal of Obesity 24(Suppl. 1): S149, 2000

Change in body weight after hormone replacement therapy in postmenopausal women is dependent on basal circulating leptin. Maturitas 30(3): 283-288, 1999

Change in body weight after hormone replacement therapy in postmenopausal women is dependent on basal circulating leptin. Maturitas 30(3): 283-288, Nov 16, 1998

Effect of hormone replacement therapy and tibolone on serum leptin levels in postmenopausal women. Maturitas 48(2): 107-113, 2004

Serum leptin levels and body composition in postmenopausal women: effects of hormone therapy. Menopause 11(4): 466-473, 2004

Effects of hormone therapy and tibolone on body composition and serum leptin levels in postmenopausal women. Fertility and Sterility 91(2): 425-431, 2008

Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women. American Journal of Epidemiology 153(11): 1094-1101, 2001

Role of postmenopausal hormone replacement therapy on body fat gain and leptin levels. Gynecological Endocrinology 20(4): 227-235, 2005

Effects of short-term hormone replacement on serum leptin levels in postmenopausal women. Clinical Endocrinology 51(4): 415-422, 1999

The influence of hormone replacement therapy (HRT) on serum leptin concentration in postmenopausal women. Maturitas 37(2): 105-111, 2001

Effects of transdermal hormone replacement therapy on levels of soluble P- and E-selectin in postmenopausal healthy women. Fertility & Sterility 77(3): 476-480, 2002

Does tibolone affect serum leptin levels and body weight in postmenopausal women?. Archives of Gynecology and Obstetrics 272(2): 127-130, 2004

Hormone replacement therapy with transdermal estradiol lowers insulin-cortisol and lipoproteins levels in postmenopausal women. Ginecologia Y Obstetricia de Mexico 70: 491-495, 2003

Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women. Clinical Endocrinology. 48(6): 691-699, E, 1998